英基 IMGN 深 沪
已收盘 02-12 16:00:00 美东时间
31.23
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 31.23
- 总市值 777.63万
- 52周最高 31.25
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.605
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 31.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.51
- 每 手 1
- 风险率 6.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
CytomX Therapeutics, Inc. announced the appointment of Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs. Dr. Gokhale will lead the company's global regulatory strategy to advance its PROBODY® pipeline, including the lead program Varseta-M, toward potential commercialization. With over 25 years of experience in regulatory affairs, Dr. Gokhale joins CytomX as it prepares for key regulatory interactions, particularly for Va...
05-18 12:00
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
Pyxis Oncology appoints Nelson Azoulay as Chief Business Officer. With over 15 years of experience in corporate strategy and biopharma transactions, Azoulay will lead corporate development and advance MICVO, the company's lead ADC targeting EDB+FN in solid tumors. MICVO is in Phase 1/2 trials for recurrent/metastatic head and neck cancer and has received FDA Fast Track Designation. Azoulay's expertise in ADCs and strategic transactions is expecte...
05-07 20:05
Prelude Therapeutics names Charles Morris chief medical officer
Prelude Therapeutics names Charles Morris chief medical officer Prelude Therapeutics named Charles Morris as executive vice president, chief medical officer effective April 20, 2026. Morris most recently served as chief medical officer at Lava Therapeutics. His prior roles include chief medical offi
04-15 19:30
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
CytomX Therapeutics, Inc. will announce its 2025 full-year financial results on March 16, 2026, before U.S. markets open. A conference call and webcast will follow at 8:00 a.m. ET / 5:00 a.m. PT. Participants can access the webcast via CytomX’s website and register in advance. CytomX, focused on developing conditionally activated biologics, is a clinical-stage oncology company advancing novel therapeutics targeting the tumor microenvironment. The...
03-04 13:00
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio授予了新任CEO Kristin Yarema 436,080股股票期权和153,505股限制性股票单位，作为其加入公司的激励。这些奖项包括四年归属期和基于 Nasdaq规则的条件。ImageneBio专注于免疫和炎症疾病治疗的开发。
2025-08-01 20:15
UPDATE 1--Charles River agrees with Elliott to add new directors, review business
Adds details on other board members in paragraph 3 By Svea Herbst-Bayliss BEVERLY HILLS, May 7 (Reuters) - Pharmaceutical company Charles River Laboratories CRL.N has reached a settlement with activis...
2025-05-07 22:10
UPDATE 1-AbbVie cuts 2025 profit forecast on acquisition expenses
Adds background in paragraphs 2, 3; details throughout April 3 (Reuters) - AbbVie ABBV.N on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition...
2025-04-04 04:48
據報每年2,500元學生津貼或被削減 倘完全取消每年料慳近20億公帑
港府下周三(26日)將發表新一年度《財政預算案》，據《星島日報》報道，在訪問多名教育界人士及立法會議員後，推測除了削減資助大學撥款外，現時毋須審查、為全港近8...
2025-02-21 12:36
